Liangyan

Liang Yan, a professor and doctoral supervisor at China Pharmaceutical University, is a visiting scholar at the University of Michigan in the United States, a candidate of the Six Talent Peaks in Jiangsu Province, a candidate of the 333 Project in Jiangsu Province, a national expert in new drug evaluation, a national GCP verification expert, a member of the Drug Metabolism Professional Committee of the Chinese Pharmacological Society, and a director of the Formula Dose Effect Research Branch of the Chinese Ethnic Medicine Society. Professor Liang is mainly engaged in the pharmacokinetic and pharmacodynamic research of traditional Chinese medicine and biomolecules, and has presided over more than 10 projects, including the National Natural Science Foundation of China and the Jiangsu Provincial Natural Science Foundation of China. Professor Liang published over 60 SCI papers as the first/corresponding author, many of which have been published in TOP journals in the field of pharmacokinetics such as APSB, BJP, JPA, ACA, DMD, etc., and have been granted 5 patents. The research results won the first prize of Jiangsu Province Science and Technology Progress Award (R3) in 2012, the first prize of the Ministry of Education Science and Technology Progress Award (R3) in 2013, and the second prize of the National Science and Technology Progress Award (R9) in 2007. 

 (1) Liang Y, et al.,Regulation of Histidine Metabolism by Lactobacillus Reuteri Mediates the Pathogenesis and Treatment of Ischemic Stroke，Acta Pharmaceutica Sinica B,2024. 

(2) Liang Y, et al., Schisandra lignans ameliorate nonalcoholic steatohepatitis by regulating aberrant metabolism of phosphatidylethanolamines, Acta Pharmaceutica Sinica B, 2023.

(3) Liang Y, et al., Aberrant branchedchain amino acid accumulation along the microbiota–gut–brain axis: Crucial targets affecting the occurrence and treatment of ischaemic stroke, British Journal of Pharmacology, 2023.

(4) Liang Y, et al., The role of phosphatidylcholine 34:1 in the occurrence, development and treatment of ulcerative colitis, Acta Pharmaceutica Sinica B, 2023.

(5) Liang Y, et al., Multiomics Profiling Reveals Protective Function of Schisandra Lignans against Acetaminophen-Induced Hepatotoxicity, Drug Metabolism and Disposition, 2020.

(6) Liang Y, et al.,Identification and Validation of Active Ingredient in Cerebrotein  Hydrolysate-I Based on Pharmacokinetic and Pharmacodynamic Studies. Drug Metabolism and Disposition, 2023.  

(7) Liang Y, et al., Exogenous glutathione exerts a therapeutic effect in ischemic stroke rats by interacting with intrastriatal dopamine. Acta Pharmacol Sin. 2022.

(8) Liang Y, et al.,Global analysis of qualitative and quantitative metabolism of Notoginsenoside R1 in rat liver-brain-gut axis based on LC-IT-TOF/MS combing mMDF strategy. Phytomedicine. 2022.  

(9) Liang Y, et al.,Exogenous glutathione exerts a therapeutic effect in ischemic stroke rats by interacting with intrastriatal dopamine. Acta Pharmacol Sin. 2022.

(10) Liang Y, et al., Insights into the Authentic Active Ingredients and Action Sites of Oral Exogenous Glutathione in the Treatment of Ischemic Brain Injury Based on Pharmacokinetic-Pharmacodynamic Studies. Drug Metab Dispos. 2020. 

Molecular mechanism and active ingredients of pseudo-ginseng on the treatment of ischemic stroke based on BCAAs metabolic regulation 

Molecular mechanism of liver protection of Schisandra chinensis based on lipid metabolism regulation

Pharmacokinetic and action targets of brain protein hydrolysates

(1) First prize of Jiangsu Province Science and Technology Progress Award (R3) 

(2) First prize of the Ministry of Education Science and Technology Progress Award (R3)

(3) Second prize of the National Science and Technology Progress Award (R9)  

Gut microbiota and drug metabolism: Chapter 10